SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.
Published in | Journal of Cancer Treatment and Research (Volume 9, Issue 3) |
DOI | 10.11648/j.jctr.20210903.12 |
Page(s) | 50-55 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
SB 365, Saponin D, Deoxypodophyllotoxin, Natural Anticancer Drug
[1] | Kang S S. Saponins from the roots of Pulsatilla koreana. Arch. Pharm Res 1989; 12 (1): 42-47. |
[2] | Kim S Y and Kim S B. Antitumor effect of Pulsatilla koreana in vitro. J Korean Cancer Asso 1994; 26 (6): 959-963. |
[3] | Kim Y, Bang S C, Lee J H and Ahn B Z. Pulsatilla saponin D: The antitumor principle from Pulsatilla koreana. Arch Pharm Res 2004; 27 (9) 95-918. |
[4] | Bang S C, Lee J H, Song G Y, Kim D H, Yoon M Y and Ahn B Z. Antitumor activity of Pulsatilla koreana saponins and their structureactivity relationship. Chem Pharm Bull 2005; 53: 1451-1454. |
[5] | Kim Y, Kim S B, You Y J and Ahn B Z. Deoxypodophylloxin; The cytotoxic and antiangiogenic component from Pulsatilla korena. Plant Medica 2002; 68: 271-274. |
[6] | Hong S W, Jung K H, Lee H S, Son M K, Yan H H, Kang N S et al. SB 365, Pulsatilla saponin D, targets C-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 2013; 34 (9): 2156-2169. |
[7] | Lee S H, Lee E and Ko Y T. Anti-inflammatory effects of a methanol extract from Pulsatilla korena in lipopolysaccharide-exposed rats. BMB Rep 2012; 45 (6): 371-376. |
[8] | Hwang J S and Kim S H. Proliferation assay of SB injection on T 3. Kim Y, Bang S C, Lee J H and Ahn B Z. Pulsatilla saponin D: The antitumor principle from Pulsatilla koreana. Arch Pharm Res 2004; 27: 915-9184. Bang and B lymphocyte in SD rat splenocytes. Biotoxtech 2001: 667-699. |
[9] | Lee J S, Kim D H, Lee C M, Ha T K, Noh K T, Park J W et al. Deoxypodophyllotoxin induces a Th 1 response and enhances the antitumor efficacy of a dendritic cell-based vaccine. Immune Netw 2011; 11 (1): 79-94. |
[10] | Son M K, Jung K H, Lee H S, Lee H S, Kim S J, Yan H H et al. SB 365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncology Reports 2013; 30: 801-808. |
[11] | Moon K S, Ji J Y, Cho Y J, Lee J H, Choi M S and Kim E E. Therapeutic effects of SB natural anticancer drug in 50 patients with stage IV pancreatic cancer. J Cancer Tre and Res 2015; 3 (3): 42-46. |
[12] | N M K, Jung K H, Hong S W, Lee H S, Zheng H M, Choi M J et al. SB 365, Pulsatilla saponin D suppress the proliferation of human colon cancer cells and induces apoptosis by modulating the AKT/mTOR signaling pathway. Food Chemistry 2013; 136: 26-33. |
[13] | Jang W J, Park B D, Jeong G S, Hong S S and Jeong C H. SB 365, Pulsatilla saponin D, suppresses the growth gefinitinib-resistant NSCLC cells with Met amplication. Oncology Report 2014; 32: 2612-2618. |
[14] | Hong S W, Jung K H, Lee H S, Choi M J, Zheng H M, Son M K et al. Apoptotic and antiangiogenic effects of Pulsatilla koreana extract on hepatocellular carcinoma. Int J Oncology 2012; 40: 452-460. |
[15] | Hong S W, Jung K H, Lee H S, Choi M J, Son M K, Zheng H M et al. SB 365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of P13K/Akt mTOR signaling pathway. Cancer Science 2012; 103: 1929-1937. |
[16] | Park B H, Jung K H, Son M K, Seo J H, Lee H S, Lee J H et al. Antitumor activity of Pulsatilla koreana extract in anaplastic thyroid cancer via apoptosis and anti-angiogenesis. Molecular Med Rep 2013; 7: 26-3017. |
[17] | Hong J M, Kim J H, Kim H M, Lee W J and Hwang Y I. SB 365, Pulsatilla saponin D induces caspase-independent cell death and augments the anticancer effect of temozolomide in glioblastma multiform cells. Molecules 2019; 24 (18), 3230. |
[18] | Lee J H, Cho Y J, Chae M S, Lee W J, Park U H and Kim E E. Initial effects of the SB natural anticancer drug on the number of NK cells, CD4+ and CD 8+ T lymphocytes in human peripheral blood. J Cancer Tre and Res 2018; 6 (2): 25-30. |
APA Style
Jong-Hwa Lee, Joo-Yeon Gie, Yoo-Jin Cho, Chul-Soo Kim, Myung-Seup Chae, et al. (2021). Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years. Journal of Cancer Treatment and Research, 9(3), 50-55. https://doi.org/10.11648/j.jctr.20210903.12
ACS Style
Jong-Hwa Lee; Joo-Yeon Gie; Yoo-Jin Cho; Chul-Soo Kim; Myung-Seup Chae, et al. Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years. J. Cancer Treat. Res. 2021, 9(3), 50-55. doi: 10.11648/j.jctr.20210903.12
AMA Style
Jong-Hwa Lee, Joo-Yeon Gie, Yoo-Jin Cho, Chul-Soo Kim, Myung-Seup Chae, et al. Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years. J Cancer Treat Res. 2021;9(3):50-55. doi: 10.11648/j.jctr.20210903.12
@article{10.11648/j.jctr.20210903.12, author = {Jong-Hwa Lee and Joo-Yeon Gie and Yoo-Jin Cho and Chul-Soo Kim and Myung-Seup Chae and Euishin Edmund Kim and Wang-Jae Lee and U-Hyun Park and Thomas Lau and Josef Sotckenreiter and Stefan Woehrer and Karl Postbauer}, title = {Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years}, journal = {Journal of Cancer Treatment and Research}, volume = {9}, number = {3}, pages = {50-55}, doi = {10.11648/j.jctr.20210903.12}, url = {https://doi.org/10.11648/j.jctr.20210903.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20210903.12}, abstract = {SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions.}, year = {2021} }
TY - JOUR T1 - Therapeutic Effects of SB 365 Natural Aticancer Drug for Various Cancers with Advanced Stages in 7 Years AU - Jong-Hwa Lee AU - Joo-Yeon Gie AU - Yoo-Jin Cho AU - Chul-Soo Kim AU - Myung-Seup Chae AU - Euishin Edmund Kim AU - Wang-Jae Lee AU - U-Hyun Park AU - Thomas Lau AU - Josef Sotckenreiter AU - Stefan Woehrer AU - Karl Postbauer Y1 - 2021/07/19 PY - 2021 N1 - https://doi.org/10.11648/j.jctr.20210903.12 DO - 10.11648/j.jctr.20210903.12 T2 - Journal of Cancer Treatment and Research JF - Journal of Cancer Treatment and Research JO - Journal of Cancer Treatment and Research SP - 50 EP - 55 PB - Science Publishing Group SN - 2376-7790 UR - https://doi.org/10.11648/j.jctr.20210903.12 AB - SB is a root extract of plant Pusatilla koreana, used traditionally as an useful antiinflammatory and antitumor agent in South Korea for long times. From March 2013 to December 2019, for 7 years there were 421 consecutive advanced and recurrent various kinds of cancer patients for intensified SB 365 anticancer drug treatment. Two important components, Pulsatilla saponin D is the most effective saponin with cancer cell apoptosis, deoxypodophyllotoxin inhibits new blood vessel formation, and anti-inflammatory effects with immune potentiative activities were confirmed. Cancer studied firstly in pancreas, followed by stomach, large intestine, lung, bile duct, liver, breast, kidney, uterus, oral cavity, esophagus and prostate. Almost of cancers were advanced and recurred status. Intravenous administration was done with intratumoral injection, intraperitoneal or intrathoracic administrations were done with change position, and inhalation therapy was also done. Side effects were clinically insignificant, most commonly fever, chills, nextly injection site pain, erythema, itching, nausea and vomitings were developed. 73.6% of total patients received 1-2 cycles of chemotherapies only, 3 cycles received patient survived for 6 months, 6 cycles survived for 12 months, and 9 cycles or more survived 30 months of survival durations. Pain control with improved appetite and immunity were noted as SB 365 treatments were going on. It is strongly requested to regain the permission of Korean FDA and prompt supports of the national medical insurance, that makes remarkable survival duration and for lesser economic burdons for advanced, recurrent cancer patients and save the funds of national medical insurance. And also highly recommended to make SB treatment available in foreign cancer patients for economic advantages and national image promotions. VL - 9 IS - 3 ER -